Search clinical trials for: CAR-T infusion

Total 21219 results

The First Affiliated Hospital of Soochow University
The First Affiliated Hospital with Nanjing Medical University; The Affiliated... and other collaborators

Recruiting

Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL

Platelet Transfusion Refractoriness | Acute Leukemia in Remission

China
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Clinical Study of Anti-CD1a CAR-T in the Treatment of R/R Acute T-lymphoblastic Leukemia/Lymphoblastic Lymphoma

Acute T-lymphoblastic Leukemia | Acute T-lymphoblastic Lymphoma

China
Memorial Sloan Kettering Cancer Center

Withdrawn

A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies

Lymphoma | Lymphoma, B-Cell | Leukemia

United States
City of Hope Medical Center
National Cancer Institute (NCI); California Institute for Regenerative Medicine...

Recruiting

HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases

Breast Cancer | HER2-positive Breast Cancer | Malignant Neoplasm | Metastatic Malignant Neoplasm in the Brain | Metastatic Malignant Neoplasm in the Leptomeninges

United States
Wuhan Union Hospital, China
Guangzhou Bio-gene Technology Co., Ltd

Not yet recruiting

A Clinical Study of CD19 CAR-T in Refractory/Moderate-to-severe Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Clinical Study of Autologous Stem Cell Transplantation + Anti-CD19 CAR T Cells for B-cell Lymphoma

B-cell Lymphoma

China
920th Hospital of Joint Logistics Support Force...

Recruiting

A Study of RD14-01 in Patients With Advanced Solid Tumors

Solid Tumor

China
920th Hospital of Joint Logistics Support Force...

Recruiting

Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

China
Fuda Cancer Hospital, Guangzhou

Withdrawn

CD19-targeting CAR T Cells for B Cell Lymphoma

B Cell Lymphoma

China
Fuda Cancer Hospital, Guangzhou

Withdrawn

Chimeric Antigen Receptor-Modified T Cells for Breast Cancer

Breast Cancer

China
CARsgen Therapeutics Co., Ltd.

Active, not recruiting

Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)

Multiple Myeloma

United States, Canada
The First Affiliated Hospital of Soochow University

Recruiting

CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia, Adult B-Cell

China
Shanghai Changzheng Hospital
CARsgen Therapeutics Co., Ltd.

Recruiting

Study of CT071 Injection in RRMM or PPCL

Multiple Myeloma | Primary Plasma Cell Leukemia

China
920th Hospital of Joint Logistics Support Force...

Recruiting

A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies

B-Cell Leukemia | B-Cell Lymphoma | B-cell Tumors

China
Sorrento Therapeutics, Inc.

Terminated

Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases (AntiCEA_CART)

Metastatic Pancreatic Carcinoma

United States
Daniel Landi

Terminated

EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma (ExCeL)

Glioblastoma | Gliosarcoma

United States
University College, London

Completed

CAR19 Donor Lymphocytes for Relapsed CD19+ Malignancies Following Allogeneic Transplantation (CARD)

CD19+ Malignancies: Relapse Post-allogeneic Transplant

United Kingdom
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies

CAR

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors

CAR | Malignant Tumors

China
Baylor College of Medicine
University of Texas, Southwestern Medical Center at Dallas

Completed

Evaluating the Use of RFT5-dgA to Deplete Alloreactive Cells Prior to Haploidentical Stem Cell Transplantation

Leukemia | Cancer

United States
Northwestern University
National Cancer Institute (NCI)

Recruiting

Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma

Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Recurrent... and other conditions

United States
Guangdong Second Provincial General Hospital

Not yet recruiting

To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
AGC Biologics S.p.A.
Horizon 2020 - European Commission

Terminated

Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma

Acute Myeloid Leukemia | Multiple Myeloma

Italy, Czechia
Mario Arpinati
European Commission

Recruiting

Multiple Donor Treg DLI for Severe Refractory Chronic GVHD (TREG2015001)

Chronic Graft Versus Host Disease

Italy
920th Hospital of Joint Logistics Support Force...

Recruiting

Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Myeloid Leukemia

Acute Myeloid Leukemia

China
Wuhan Union Hospital, China
Wuhan Si'an Medical Technology Co., Ltd

Recruiting

T Cells Expressing a Bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple Myeloma

CS1+ or BCMA+ Multiple Myeloma

China
Sorrento Therapeutics, Inc.

Completed

Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients

Relapsed or Refractory Multiple Myeloma

United States
Massachusetts General Hospital
Dana-Farber Cancer Institute; University of Regensburg

Completed

Infusion of T-Regulatory Cells in Kidney Transplant Recipients (The ONE Study)

Kidney Failure, Kidney Transplant

United States
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

Acute Lymphoblastic Leukemia, in Relapse | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory | Acute Lymphocytic Leukaemia Refractory

China
BioSyngen Pte Ltd

Completed

A Phase 1 Study of BRG01 in Subjects With Relapsed/Metastatic Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma

EBV-positive Nasopharyngeal Carcinoma

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies

Lymphoma | Multiple Myeloma | Acute Lymphoblastic Leukemia

China
Bezmialem Vakif University
Muğla Sıtkı Koçman University; The Scientific and Technological Research Council... and other collaborators

Active, not recruiting

Food Reward Circuit Change by Orthodontics (DTI)

Eating Disorders | Eating Behavior | Orthodontic Appliance Complication | Eating Habit

Turkey
Nexcella Inc.

Not yet recruiting

Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis (NEXICART-2)

Light Chain (AL) Amyloidosis

United States
Bellicum Pharmaceuticals

Suspended

Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Solid Tumor, Adult | HER-2 Gene Amplification | HER-2 Protein Overexpression

United States
Celyad Oncology SA
National Heart, Lung, and Blood Institute (NHLBI); Dana-Farber Cancer Institute

Completed

Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands

Acute Myeloid Leukemia | Multiple Myeloma | Myelodysplastic Syndrome

United States
Fundación Pública Andaluza para la gestión de la...

Recruiting

Donor Regulatory T-cells for cGVHD in Patients Who do Not Obtain Complete Remission With Ruxolitinib (Treg4GVHD)

Chronic Graft vs Host Disease

Spain
H. Lee Moffitt Cancer Center and Research Institute
Florida Department of Health

Recruiting

Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT

Acute Myeloid Leukemia

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma

Multiple Myeloma

United States
Fundación Pública Andaluza para la gestión de la...

Completed

Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-host-Disease (GVHD-TReG)

Chronic Graft vs Host Disease

Spain
University of Sydney

Unknown

Combined Infusion of Cytotoxic T-Lymphocytes and Vaccination (CYNTAX)

Complication of Transplant

Australia
Insel Gruppe AG, University Hospital Bern

Not yet recruiting

PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab) (PRONTO)

Lymphoma | Leukemia | Myeloma

Switzerland
Mitchell Horwitz, MD

Completed

Naive T-Cell Depleted DLI Following Allo Stem Cell Transplant

Hematological Malignancies

United States
The University of New South Wales

Completed

Faecal Microbiota Transplantation in Ulcerative Colitis (FOCUS)

Ulcerative Colitis | Inflammatory Bowel Disease

Australia
Southwest Hospital, China

Unknown

the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)

Lymphoma, Large B-Cell, Diffuse

China
University of Freiburg

Completed

Multicenter Study Using IMC to Analyze the Impact of ICANS on Microglia

CAR T-Cell-Related Encephalopathy Syndrome | ICANS, Grade Unspecified

Germany
Fuda Cancer Hospital, Guangzhou

Withdrawn

CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients

CAR-T Cell Immunotherapy | Glioma of Brain
Wuhan Sian Medical Technology Co., Ltd
Wuhan Union Hospital, China; Xiangyang Central Hospital; Jingzhou Central Hospital and other collaborators

Unknown

CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies

B Cell Lymphoma | Acute Lymphoblastic Leukemia

China
Medical College of Wisconsin
Children's Hospital and Health System Foundation, Wisconsin

Completed

Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell

Lymphoma, B-Cell | Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma

Multiple Myeloma | New Diagnosis Tumor

China
Peking University People's Hospital

Not yet recruiting

CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma

T-cell Non-Hodgkin's Lymphoma

Search clinical trials for: CAR-T infusion

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations